TY - JOUR
T1 - Historical perspective of carotid artery stenting in Japan
T2 - Analysis of 8,092 cases in the Japanese CAS survey
AU - Miyachi, Shigeru
AU - Taki, Waro
AU - Sakai, Nobuyuki
AU - Nakahara, Ichiro
N1 - Funding Information:
S. Miyachi has received funding from the Foundation for Biomedical Research and Innovation.
Funding Information:
This study was supported by The Japanese Society for Neuroendovascular Therapy (non-financial support). The authors are very grateful to all the study participants and collaborators. Also, we thank Dr. Nobuyuki Hamajima, Department of Preventive Medicine, Nagoya University Graduate School of Medicine, for statistical analysis and Drs. Takashi Izumi and Noriaki Matsubara, The Neuroendovascular Team, Department of Neurosurgery, Nagoya University Graduate School of Medicine, for their generous assistance with data analysis and preparing this manuscript.
Funding Information:
This study was financially supported by the research grant program of Nagoya University.
PY - 2012/12
Y1 - 2012/12
N2 - Background and purpose We conducted a large retrospective survey of the clinical results of carotid artery stenting (CAS) for about 10 years performed by neurointerventionists at 43 Japanese institutions. Hence, the historical perspective of CAS in Japan was demonstrated. Methods Cases were stratified into three separate periods based on the approval status of devices: the first period, in which off-label CAS was performed using balloon protection; the second period, using a limited number of approved devices under filter protection; the third period, using appropriate protection selected from several different options based on the preoperative evaluation (tailored CAS). Clinical results were retrospectively evaluated. Then 30-day results of each period were examined. The major adverse event (MAE) was defined as stroke, myocardial infarction or death. Results Between January 2001 and December 2010, a total of 8,092 cases were registered, including 4,072, 1,526 and 2,494 in the first, second and third period, respectively. In the first period, 92 % of CAS was performed under balloon protection. In contrast, 91 % was done under filter protection in the second period. In the third period, various protection methods were used, including balloon (31 %), filter (50 %) and proximal protection (18 %). The rate of MAE at 30 days was 6.1 %, 10.2 % and 3.5 % in the first, second and third periods, respectively, and 6.3 % in all periods combined. The rate of MAE in the third period was significantly lower than that in the first and second periods. Conclusions The historical paradigm of CAS in Japan was demonstrated. Due to the improvement of devices, increasing experience and appropriate selection of protection, CAS is continuing to evolve into a safer and more efficacious method of stroke prevention.
AB - Background and purpose We conducted a large retrospective survey of the clinical results of carotid artery stenting (CAS) for about 10 years performed by neurointerventionists at 43 Japanese institutions. Hence, the historical perspective of CAS in Japan was demonstrated. Methods Cases were stratified into three separate periods based on the approval status of devices: the first period, in which off-label CAS was performed using balloon protection; the second period, using a limited number of approved devices under filter protection; the third period, using appropriate protection selected from several different options based on the preoperative evaluation (tailored CAS). Clinical results were retrospectively evaluated. Then 30-day results of each period were examined. The major adverse event (MAE) was defined as stroke, myocardial infarction or death. Results Between January 2001 and December 2010, a total of 8,092 cases were registered, including 4,072, 1,526 and 2,494 in the first, second and third period, respectively. In the first period, 92 % of CAS was performed under balloon protection. In contrast, 91 % was done under filter protection in the second period. In the third period, various protection methods were used, including balloon (31 %), filter (50 %) and proximal protection (18 %). The rate of MAE at 30 days was 6.1 %, 10.2 % and 3.5 % in the first, second and third periods, respectively, and 6.3 % in all periods combined. The rate of MAE in the third period was significantly lower than that in the first and second periods. Conclusions The historical paradigm of CAS in Japan was demonstrated. Due to the improvement of devices, increasing experience and appropriate selection of protection, CAS is continuing to evolve into a safer and more efficacious method of stroke prevention.
UR - http://www.scopus.com/inward/record.url?scp=84871075338&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84871075338&partnerID=8YFLogxK
U2 - 10.1007/s00701-012-1508-9
DO - 10.1007/s00701-012-1508-9
M3 - Review article
C2 - 23053283
AN - SCOPUS:84871075338
SN - 0001-6268
VL - 154
SP - 2127
EP - 2137
JO - Acta Neurochirurgica
JF - Acta Neurochirurgica
IS - 12
ER -